This week, four Pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This week, Johnson & Johnson (NYSE:JNJ) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, and Equity, JNJ also gets A’s. The current dividend yield is 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.

Bristol-Myers Squibb Company (NYSE:BMY) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. The stock price has risen 9.1% over the past month, better than the 1.7% decrease the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BMY stock.

Watson Pharmaceuticals (NYSE:WPI) shows solid improvement this week. The company’s rating rises from a B to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

This week, Repros Therapeutics’ (NASDAQ:RPRX) ratings are up from a B last week to an A. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.